APPRAISAL OF NIMESULIDE EFFICIENCY, TOLERANCE AND SAFETY AMONG CHILDREN WITH JUVENILE ARTHRITIS

E.I. Alexeeva; S.I. Valieva

APPRAISAL OF NIMESULIDE EFFICIENCY, TOLERANCE AND SAFETY AMONG CHILDREN WITH JUVENILE ARTHRITIS

E.I. Alexeeva, S.I. Valieva

Abstract

The article analyzes nimesulide application experience among children with juvenile arthritides against the insufficient efficiency of a therapy by other non steroid anti-inflammatory medications. The researchers show that nimesulide is an efficient non steroid anti-inflammatory medication for the patients, suffering from oligo- and limited poly arthritis of the I–II activity degree. Nimesulide also provided for the reliable regression of the clinical and laboratory activity manifestations of a disease and, what is more important, among most patients without applications of the local glucocorticosteroidbassisted therapy. Nimesulide is characterized by good tolerance and low toxicity, which is along with the permit to use it among children aged 2 and over, allows one to consider this drug as one of the medications to choose for the treatment of the inflammatory joint diseases among children.
Key words: children, juvenile arthritis, nimesulide.

About the Authors

E.I. Alexeeva

Scientific Center of Children's Health, Russian Academy of Medical Sciences, Moscow
Russian Federation

S.I. Valieva

Scientific Center of Children's Health, Russian Academy of Medical Sciences, Moscow
Russian Federation

References

1. Насонов Е.Л., Лазебник Л.Б., Мареев В.Ю. и соавт. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. М. 2006. С. 10–22, С. 34–55.

2. Насонов Е.Л. Нестероидные противоспалительные препараты (Перспективы применения в медицине). М.:Анко. 2000. 142 с.

3. Hawkey C. Cyclooxygenase inhibition: between the devil and deep blue see. GUT. 2002; 50: 1125-1130.

4. Каратеев А.Е., Каратеев Д.Е., Лучихина Е.Л. и соавт. Эффективность и безопасность монотерапии высокими дозами НПВП при раннем артрите. РМЖ. 2006; 16: 24–29.

5. Каратеев А.Е., Насонова В.А. Распространенность, структура и факторы риска развития гастропатий, индуцированных НПВП. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2000; 4: 34-39.

6. Никишина И.П., Кузьмина Н.Н., Каратеев А.Е. Опыт использования фамосана (фамотидина) в лечении гастродуоденопатий у больных ювенильными хроническими артритами на фоне длительного приема нестероидных и стероидных противовоспалительных препаратов. Материалы VIII съезда педиатров России. М. 1998. С. 194–195.

7. Brun J., Jones R. Nonsteroidal anti-inflammatory drug-associated dyspepsia: the Scale of the problem. Am. J. Med. 2001; 110: 12–13.

8. Avidan B., Sonnenberg A., Schnell T.G. et al. Risk factors of oesophagitis of arthritic patients. Eur. J. Gastroenterol. Hepatol. 2001; 13: 1095–1099.

9. Jones J. Nonsteroidal anti–inflammatory drug associated dyspepsia: basis mechanisms and future research. Am. J. Med. 2001; 110: 14–18.

10. Talley N.J., Evans J.M., Fleming K.C. et al. Nonsteroidal anti-inflammatory drugs and dyspepsia in the elderly. Dig. Dis. Sci. 1995; 40: 1345–1350.

11. De Pouvourville G. The iatrogenic cost of non steroidal anti–inflammatory drag therapy. Br. J. Rheumatol. 1995; 34: 19–24.

12. Насонов Е.Л. Эффективность и переносимость нестероидного противовоспалительного препарата Нимесулид: новые данные. РМЖ. 2001; 15: 6–8.

13. Насонов Е.Л. Перспективы применения нового нестероидного противовоспалительного препарата нимесулид. Клиническая фармакология и терапия. 1999; 1: 65–69.

14. Fusetti G., Magni E., Armandola M. Tolerability of nimesulide. Epidemiological data. Drugs. 1993; 46: 277–280.

15. Traversa G., Bianchi C., Da Cas R. et al. Cohort study of hepatotoxity associated with nimesulide and other nonsteroidal anti-inflammatory drugs. BMJ. 2003; 327: 18–22.

16. Conforti A., Leone R, Moretti U. et al. Adverse drug reactions related to the use of NSAIDs with a focus on nimesulide: results of spontaneous reporting from a Northern Italian area. Drug. Saf. 2001; 24: 1081–1090.

17. Rainsford K.D. Relationship of nimesulide safety to its pharmacokinetics; assessment of adverse reactions. Rheumatology. 1999; 38 (Suppl.1): 4–10.

18. Merlani G, Fox M, Oehen HP, et al. Fatal hepatotoxicity secondary tо nimesulide. Eur. J. Clin. Pharmacol. 2001; 57: 321–326.

19. Saha K. Use of nimesulide in Indian children must be stopped. BMJ. 2003; 326–713.

20. Kumar S. Drug linked to child deaths is still available in India. BMJ. 2003; 326–770.

21. Van Steenbergen W., Peeters P., De Bondt J. et al. Nimesulide- induced acute hepatitis; evidence from six cases. J. Hepatol. 1998; 29: 135–141.

22. Weiis P., Mouallem M., Bruck R. et al. Nimesulide induced hepatitis and acute liver failure. Isr. Med. Assoc. J. 1999; 1: 89–91.

23. Никишина И.П., Родионовская С.Р., Малиевский В.А. и соавт. Нимесулид в практике детского ревматолога. Вопросы современной педиатрии. Приложение. Ревматические болезни. 2006; 5 (2): 12–18.

24. Bombardier C., Lane L., Reicin A. et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid artritis. New Engl. J. Med. 2000; 343.

Review

For citations:

Alexeeva E., Valieva S. APPRAISAL OF NIMESULIDE EFFICIENCY, TOLERANCE AND SAFETY AMONG CHILDREN WITH JUVENILE ARTHRITIS. Current Pediatrics. 2007;6(6):76-80.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International.

ISSN 1682-5527 (Print)
ISSN 1682-5535 (Online)

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

User

Current Pediatrics

APPRAISAL OF NIMESULIDE EFFICIENCY, TOLERANCE AND SAFETY AMONG CHILDREN WITH JUVENILE ARTHRITIS

Abstract

About the Authors

References

Review

For citations:

Cookies policy